Literature DB >> 8568113

Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.

C Serfaty-Lacrosniere1, R J Wood, D Voytko, J R Saltzman, M Pedrosa, T E Sepe, R R Russell.   

Abstract

OBJECTIVE: Low gastric pH is generally believed to be an important factor in intestinal mineral absorption. Thus, hypochlorhydria could be an important risk factor for mineral malabsorption and the development of marginal mineral status. We studied whether the hypochlorhydria associated with treatment with the anti-ulcer medication omeprazole, a potent gastric proton pump inhibition, would affect intestinal calcium, phosphorus, magnesium, or zinc absorption from food.
METHODS: Thirteen normal, healthy adults were assigned to either a control group (n = 5) receiving no drug treatment or an omeprazole treatment group (n = 8) to produce increased gastric pH. Omeprazole treatment of normal volunteers resulted in a significant change in postprandial gastric pH (pH 6.4 +/- 0.3 vs. 3.6 +/- 0.5 in control subjects, p < 0.01) and baseline fasting pH (pH 5.8 +/- 0.5 vs. pH 1.8 +/- 0.3 in controls, p < 0.01) after an overnight fast. Net mineral absorption from a standard test meal was measured using a whole gut lavage technique. Mineral absorption was measured twice in each subject, once with 120 mL of 0.1 mol/liter hydrochloric acid and a second time with 120 mL of distilled water alone.
RESULTS: We found that despite marked changes in gastric pH due to drug treatment or administration of exogenous HCl, no change in the intestinal absorption of calcium, phosphorus, magnesium or zinc from a standard test meal was evident.
CONCLUSIONS: These findings suggest that changing the gastric pH alone does not modify the net intestinal absorption of several minerals from food. Therefore, it is unlikely that moderate hypochlorhydria resulting from short-term omeprazole treatment substantially increases the risk for developing calcium, phosphorus, magnesium, or zinc deficiencies due to mineral malabsorption.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568113     DOI: 10.1080/07315724.1995.10718522

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  44 in total

1.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Authors:  Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen
Journal:  Arch Intern Med       Date:  2010-05-10

Review 2.  Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents.

Authors:  David A Johnson
Journal:  Curr Gastroenterol Rep       Date:  2010-06

Review 3.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.

Authors:  Matthew J Wright; Rebecca R Sullivan; Erin Gaffney-Stomberg; Donna M Caseria; Kimberly O O'Brien; Deborah D Proctor; Christine A Simpson; Jane E Kerstetter; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

5.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

6.  Omeprazole and refractory hypomagnesaemia.

Authors:  N Shabajee; E J Lamb; I Sturgess; R W Sumathipala
Journal:  BMJ       Date:  2008-07-10

7.  Hip fracture risk in patients with a diagnosis of pernicious anemia.

Authors:  Nathan A Merriman; Mary E Putt; David C Metz; Yu-Xiao Yang
Journal:  Gastroenterology       Date:  2009-12-21       Impact factor: 22.682

Review 8.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

Review 9.  Osteoporosis and polypharmacy.

Authors:  M Gosch; M Jeske; C Kammerlander; T Roth
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

Review 10.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.